Azathioprine
Azathioprine is a complementary immunosuppressive drug
Tablets, azathioprine 50 mg
Injection, (powder for injection solution) Azathioprine (as sodium salt), 100 mg Vial
Uses: to prevent rejection in bait recipients; rheumatoid arthritis; inflammatory bowel disease.
Contraindications: hypersensitivity to azathioprine and mercaptopurine; breast-feeding.
Precautions: To monitor toxicity throughout the treatment period; a full blood count should be performed every week (or more for larger doses and renal or hepatic impairment) for 4 weeks of treatment and at least 3 months thereafter; Renal impairment; liver disease.
Suppression of bone marrow. Patients should be warned to immediately report any signs or symptoms of bone marrow suppression, such as unexplained bruising, bleeding or infection.
Dosage:
Rejection of bait, oral or intravenous (for at least 1 minute followed by 50 ml sodium intravenous infusion) or intravenous infusion, ADULT up to 5 mg / kg on surgery day, then reduced to 1-4 mg / kg daily according to the response to sustainability.
Restructuring and giving. As directed by the manufacturer.
Note: Intravenous injection is very alkaline and irritating; intravenous injection should only be used if oral administration is not possible.
Hypersensitivity reactions include allergic reactions including dizziness, vomiting, fever, muscle pain, arthralgia, rash, hypotension or renal renal inflammation requiring immediate abstinence; blood poisoning including leukopenia and thrombocytopenia (reversible when refraining from use) ; Hair loss; increased exposure to infections and colitis in patients who are also taking corticosteroid nausea; rarely pancreatitis, pneumonia, and hepatic hepatic disease.
Azathioprine is a complementary immunosuppressive drug
Tablets, azathioprine 50 mg
Injection, (powder for injection solution) Azathioprine (as sodium salt), 100 mg Vial
Uses: to prevent rejection in bait recipients; rheumatoid arthritis; inflammatory bowel disease.
Contraindications: hypersensitivity to azathioprine and mercaptopurine; breast-feeding.
Precautions: To monitor toxicity throughout the treatment period; a full blood count should be performed every week (or more for larger doses and renal or hepatic impairment) for 4 weeks of treatment and at least 3 months thereafter; Renal impairment; liver disease.
Suppression of bone marrow. Patients should be warned to immediately report any signs or symptoms of bone marrow suppression, such as unexplained bruising, bleeding or infection.
Dosage:
Rejection of bait, oral or intravenous (for at least 1 minute followed by 50 ml sodium intravenous infusion) or intravenous infusion, ADULT up to 5 mg / kg on surgery day, then reduced to 1-4 mg / kg daily according to the response to sustainability.
Restructuring and giving. As directed by the manufacturer.
Note: Intravenous injection is very alkaline and irritating; intravenous injection should only be used if oral administration is not possible.
Hypersensitivity reactions include allergic reactions including dizziness, vomiting, fever, muscle pain, arthralgia, rash, hypotension or renal renal inflammation requiring immediate abstinence; blood poisoning including leukopenia and thrombocytopenia (reversible when refraining from use) ; Hair loss; increased exposure to infections and colitis in patients who are also taking corticosteroid nausea; rarely pancreatitis, pneumonia, and hepatic hepatic disease.
